Thesis
CARDAMYST's PSVT launch trajectory and AFib-RVR expansion define whether etripamil becomes a multi-indication antiarrhythmic franchise
CARDAMYST (etripamil), an intranasal calcium channel blocker, is approved for acute PSVT conversion in adults with early commercial traction across ~400 prescribers. The thesis turns on whether CARDAMYST achieves durable payer coverage and formulary penetration sufficient to fund operations while the AFib-RVR Phase 3 generates sNDA-enabling data. The primary risks are displacement by vagal maneuver guidance updates or IV adenosine's entrenched emergency-use dominance, and the high commercial cost of building a specialty cardiology sales footprint as an independent.
Focus
AFib-RVR Phase 3 trial first patient enrollment
H2 2026
Bull
Successful Phase 3 initiation with strong enrollment velocity would validate the AFib-RVR development pathway and demonstrate that the existing PSVT safety database can support an accelerated sNDA regulatory strategy. A clean trial launch would signal to investors that etripamil's self-administered nasal spray format offers a differentiated, patient-empowering approach to acute rate control in AFib-RVR, opening a patient population meaningfully larger than PSVT and repositioning MIST as a multi-indication antiarrhythmic platform.
Bear
The most likely disappointment scenarios are enrollment delays driven by site activation challenges or payer/patient reluctance to enroll given the already-approved CARDAMYST option muddying investigator incentives, or FDA pushback on the proposed sNDA pathway requiring a full standalone NDA with broader safety data. A slow or stalled enrollment signal would raise doubts about the commercial addressability of AFib-RVR and leave the investment thesis dependent entirely on PSVT launch trajectory, which, while positive, reflects a narrower market opportunity.
Unlock the full thesis for MIST.
The living thesis log, full pipeline, competitive landscape, and the ability to ask anything — updated automatically as the story changes.
Start your 7-day free trialRelated companies
Generated automatically from SEC filings, trial readouts, and earnings calls. For informational purposes only. Not financial advice.